Physician profile
Maria L Escolar
NPI 1366552812
$42,385.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $9,179 · 2022: $5,245 · 2023: $6,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16,676.97 | 2020-2022 | |
| Chiesi USA, INC. | $9,800.00 | 2021-2023 | |
| Shire North American Group INC | $5,067.41 | 2019 | |
| Travere Therapeutics, INC. | $3,432.89 | 2019 | |
| Sanofi US Services INC. | $2,679.00 | 2021 | |
| Janssen Global Services, LLC | $1,620.00 | 2022 | |
| Allergan, INC. | $1,150.00 | 2019 | |
| Zoll Medical Corporation | $1,000.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $533.33 | 2019 | |
| Biomarin Pharmaceutical INC. | $375.00 | 2019 | |
| Horizon Therapeutics Plc | $50.47 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Escolar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.